Results 121 to 130 of about 801,812 (294)

Cutaneous malignant melanoma in situ: A Danish cross-sectional study on patient and tumour characteristics in 144 cases

JPRAS Open, 2015
Introduction: Cutaneous malignant melanoma in situ (MIS) has not been subject to much attention or investigation. Little is known of the characteristics of patients and tumours.
Anders Klit, Cecilie Brandt Lassen, Caroline Holkmann Olsen, Jørgen Lock-Andersen   +3 more
doaj   +1 more source

Avaliação in vitro dos efeitos citotóxicos e antimetastáticos de sais de isotiourônio, de n-fenilisotiourônio e de isotiossemicarbazidas em linhagens de melanoma [PDF]

, 2014
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2014.O melanoma é um tipo de câncer de pele extremamente agressivo, devido à alta propensão em produzir ...
Cisilotto, Júlia
core  

Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A‐Dependent CXCL5 Upregulation

Advanced Science, EarlyView.
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun, Hengjie Xu, Sheng Yang, Jiahui Zhou, Chuanxin Tian, Hongxu Nie, Chi Jin, Tuo Wang, Zhihao Chen, Junwei Tang, Yifei Feng, Xiaowei Wang, Yueming Sun   +12 more
wiley   +1 more source

circZNF148 Drives Glucose Metabolism Reprogramming to Enhance Metastasis and Immune Evasion via HK1 Stabilization in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
CircZNF148 stabilizes HK1 through deubiquitinase recruitment, thereby enhancing glycolysis and lactate production. Elevated lactate promotes PD‑L1 lactylation and membrane accumulation while suppressing CD8+ T‐cell cytotoxicity, collectively facilitating immune evasion and malignant progression in TNBC.
Yuhan Jin, Wenjing Zhao, Lei Wang, Jianing Wang, Keying Zhao, Dan Luo, Yifei Wang, Yuxia Yang, Jingze Yang, Yaming Li, Tong Chen, Dianwen Han, Zekun Wang, Xiaoyan Li, Bing Chen, Lijuan Wang, Yiran Liang, Qifeng Yang   +17 more
wiley   +1 more source

Association of MC1R Variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study [PDF]

, 2010
<p><b>Background</b> Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes,
Pastorino, L., Melanoma Genetics Consortium, Goldstein, A M, Taylor JC, Ming M, Taylor Y, Martin NG, PUIG S, Rull R, Gliori S, Holland EA., Gonzalez M, Calista, D, Mackie, R.M., Lindén D, N. K. Hayward, Randerson-Moor, J, Palou J, Vilalta A, Ming, M. E., V. Höiom, Belle, P. van, Conill C, Gillanders, E, Avril, M.F., Vidal-Sicart S, Carrera, C., Bishop, J.A.N., Lang, J. M., Bishop, D. T., Mohamdi, H., GRUIS N, Bressac-de Paillerets, B, BIANCHI-SCARRÀ G, Gruis NA, P. A. Kanetsky, Bressac-de Paillerets, B., Malvehy J, N. Gruis, Whiteman DC, CARRERA C, Hayward, N. K., Tucker, M.A., G. J. Mann, van der Velden, P, Badenas C, R. M. Mackie, Stark, M., Nasti S, Marti-Laborda R, GenoMEL, Harbst K, V. Chaudru, RANDERSON-MOOR J, B. Bressac-de Paillerets, C. Ingvar, ELDER DE, PASTORINO L, J. Randerson-Moor, Tsao, H, Mohamdi, H, Landi G, Cuellar F, HAYWARD NK, AVRIL MF, Brassac-de Paillerets, B., Minghetti P, van Belle, P., Carrera, C, C. J. Njauw, Kanetsky P, GenoMEL,, E. Gillanders, A. M. Goldstein, Calista, D., Hayward, N K, Gargiulo S, W. BRUNO, Kanetsky, P.A., Arguís P, Bianchi-Scarra, G., L. Pastorino, D. E. Elder, Bertazzi PA, BERGMAN W, Chaudru, V, Mackie, R M, HÖIOM V, Battistuzzi L, Duffy DL, Origone P, Elder, D. E., Holland, E.A., HANSSON J, MacGregor S, MANN GJ, TUCKER MA, Mack T, Lang, J.M., F. Demenais, X. R. Yang, Ancero A, de Lichy M, Newton Bishop, J. A., Bianhi-Scarrà G, Landi, MT, Leake S, Mann, G J, Landi, M.T., VAN BELLE P, Stark, M, Hayward, N.K., van Mourik L, Yang, X.R., Parossian S, Demenais, F, Nielsen K, Elder, D.E., Tsao, H., Arcangeli F, Montgomery GW, MOHAMDI H, CHAUDRU V, J. Palmer, Mackie, R., M. E. Ming, Demenais, F., AZIZI E, Ming, M E, M. T. Landi, Azizi, E., Holland, E A, Randerson-Moor, J., Alós L, Gruis, N, Olsson, Håkan, J. M. Lang, van Nieuwpport FA, Castel T, LANDI MT, LANG JM, M. F. Avril, Haynes S, Kanetsky, P. A., Queirolo P, Karpavicius B, BISHOP DT, Palmer, J., M. Harland, Hogg, D., J. Hansson, CALISTA D, VAN DER VELDEN P, van der Velden, P., Yang, X R, Chaudru, V., Bergman, W., van Belle, P, Chan M, Höiom, V, BRUNO W, Kanetsky, P A, PALMER J, NJAUW CJ, Lang, J., H. Tsao, Sánchez M, G. Bianchi-Scarrà, Vilella R, NEWTON BISHOP JA, Avril, M F, Maubec E, Goldstein, A.M., P. van der Velden, J. A. Newton Bishop, KANETSKY PA, Mila M, Hoiom, V., Melanoma Genetics Consortium: Demenais F, H. Olsson, BRESSAC-DE PAILLERETS B, Harland, M, Tuominen R, E. A. Holland, Affleck P, Whittaker L, Loo JC, Mackie, R. M., Tesema L, Njauw, C. J., Iles MM, Borg Å, Holland, E. A., Ingvar, Christian, MACKIE RM, Hansson, J., HOLLAND EA, GHIORZO P, Butille JA, Cervera R, Ogbah Z, Azizi, E, Bishop, D.T., C. Carrera, Velden, P. van der, Landi, M. T., Campo A, Ming, M.E., Newton Bishop, J A, Jeannin P, Lang, J M, Bishop, D T, MING ME, Njauw, C J, E. Azizi, HARLAND M, Lang J, M. A. Tucker, Elder D, Gabriel D, Gruis, N., Gillanders, E., W. Bergman, Lesueur F, Capirossi D, DEMENAIS F, STARK M, Mackie R, Ingvar, C., GILLANDERS E, Njauw, C.J., P. van Belle, Barrett JH, GOLDSTEIN AM, M. Stark, Hogg, D, Iglesias P, Puig, S., D. Hogg, Elder, D E, INGVAR C, Kukalizch K, Mann, G.J., Olsson, H., Bergman, W, Pastorino, L, Mann, G. J., S. Puig, Schmid H, Tucker, M A, D. Calista, Mitra N, TSAO H, YANG XR, Kefford RF, P. GHIORZO, Njauw CN, Avril, M. F., Jönsson G, Harrison J, HOGG D, Ruffin A, Aguilera P, D. T. Bishop, Corda E, OLSSON H, Puig, S, Hansson, J, Palmer, J, Bianchi-Scarrà, G, H. Mohamdi, Måsbäck A, Newton Bishop, J.A., Harland, M., Goldstein, A. M., Olsson, Håkan,, Bishop, DT, Ingvar, Christian,, Hayward, NK, Bishop, JAN, Lund University., Goldstein, AM, Kanetsky, PA, Elder, DE   +283 more
core   +1 more source

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

Advanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui, Yuening Sun, Ziyang Liu, Xuntao Lai, Yunshu Zhao, Yan'er Wang, Yuanming He, Fang Xu, Du Feng, Longlong Liu, Zhenqian Huang, Lijie Xing, Xinliang Mao   +12 more
wiley   +1 more source

Macrophage PABPC4‐SPP1 Axis Orchestrates Immunosuppression in Colorectal Cancer

Advanced Science, EarlyView.
In the CRC microenvironment, macrophage PABPC4 binds to the 3′UTR of SPP1 mRNA to stabilize its expression, thereby sustaining M2‐like immunosuppressive macrophage polarization. Concurrently, this axis suppresses CD8+ T cell effector functions via CD44 signaling, collectively fostering an immunosuppressive niche that drives tumor progression.
Meng Wang, Fang Yang, Yuan Gao, Liuli Li, Yulan Huang, Hui Yao, Sijie Zhao, Kun Zhao, Tianying Zhang, Hui Heng, Jiaxin Xu, Yuancai Xiang, Weidong Xiao, Shaofan Hu, Hongming Miao   +14 more
wiley   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

Advanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai, Xin Mei Zhang, Jing Cheng Zhang, Xu Ting Deng, Qiao Liu, Mustafa Hussein Ali, Fang Zhou Yin, Wu Yin   +7 more
wiley   +1 more source